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Introduction: Perampanel (PER) is a non-competitive AMPA glutamate receptor
antagonist approved for focal and generalized seizures as add-on therapy. PER does not
seem to negatively affect the cognitive profile in children and adolescents, but its influence
on visuospatial abilities is still to be assessed. The aim of our study was to assess
visuospatial skills through a standardized neuropsychological evaluation in adolescents
taking PER for 12 months.
Methods: Our sample included 46 adolescents aged 12–18 years with focal and
generalized drug-resistant epilepsy already in therapy with one or two antiseizure
medications. Changes in visuospatial perception and memory were assessed by the
Rey–Osterrieth Complex Figure Test at baseline (before taking PER) and after 12 months
of pharmacological treatment. Executive functions and non-verbal intelligence were also
assessed at baseline.
Results: After 12 months of PER therapy, the mean scores on the Rey–Osterrieth
Complex Figure Test remained almost unchanged for both visuospatial perception
and visuospatial memory skills. At baseline, visuospatial memory was related to
executive function, and visuospatial perception was related to executive function and
non-verbal intelligence.
Conclusions: Adjunctive treatment with PER did not negatively affect visuospatial skills.
No adverse event effects have been reported after 12 months of follow-up, and this
suggests a good tolerability in the middle-to-long term.
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INTRODUCTION
Perampanel (PER) is a relatively new antiseizure medication (ASM), approved as an additional
treatment for focal-onset seizures with or without loss of awareness and primary generalized
seizures in epileptic patients aged 4 years and older (1–3). Its peculiarity consists of a novel
mechanism of action, different from other ASMs: PER is a selective, non-competitive antagonist
to the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, an ionotropic
glutamate receptor, that plays a basic part in fast excitatory synaptic transmission (4). Three
phase III randomized controlled studies and subsequent open-label extension studies demonstrate
the efficacy of PER as an add-on treatment of refractory focal seizures in adolescents (5–9).
A subsequent multicenter, randomized, placebo-controlled study showed its efficacy in primary
generalized tonic-clonic seizures in 164 patients aged 12 years and older (10).
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More recently, other studies also highlighted good efficacy
of PER in children from 4 years of age with different types
of drug-resistant seizures (11, 12). Studies in the literature on
the safety and efficacy of PER in children and adolescents have
shown an overall favor risk–benefit profile with generally mild or
moderate adverse effects (AEs). The most common AEs reported
were dizziness (20.4%), drowsiness (15.3%), aggression (8.2%),
decreased appetite (6.1%), and rhinitis (5.1%). It appears that the
incidence of AEs is lower with a slower titration rate and that the
AEs are reversible with the discontinuation of PER or with a dose
adjustment (13).
In more recent years, tolerability research has paid increasing
attention to the AEs of ASMs on cognitive function, especially
in children and adolescents, whose central nervous system is still
developing (14, 15). Regarding PER, the data currently available
seem encouraging. A recent randomized, placebo-controlled
study in adolescents with epilepsy revealed that PER had no
negative effects on the global cognitive profile (16). Furthermore,
executive functions, such as attention and working memory, also
did not appear to be negatively affected by add-on therapy with
PER in adolescent patients (17).
With the present study, we tried to fill a gap in the literature,
by focusing on visual–spatial cognitive abilities and their changes
during PER therapy. These abilities are important in various
of contexts and human actions, such as movement, non-verbal
communication, spatial orientation, spatial representation,
graphic production, geometric recognition, and in disparate
types of problem solving and academic achievements (18, 19).
Therefore, the primary aim of our prospective observational
study was to evaluate visual–spatial skills through the use of
standardized tests in adolescents with focal and generalized drug-
resistant epilepsy at baseline and after 12 months of add-on
treatment with PER.
A secondary objective of our study was to correlate
visuospatial skills with executive functions, non-verbal
intelligence and some demographics and epilepsy-related
characteristics (age, sex, epilepsy duration, age at onset
of epilepsy, frequency of seizure, seizure type, ASM
number, PER dose).
MATERIALS AND METHODS
Study Design and Participants
Our work is a prospective observational study. The patients were
consecutively recruited at the Child Neuropsychiatry Unit of the
University of Salerno from January 2016 to January 2020.
The eligibility criteria were as follows: focal or generalized
epilepsy not well-controlled by drug therapy with one or
two anticonvulsant drugs, non-verbal IQ above the fifth
percentile [intelligence quotient (IQ) ≥ 70] evaluated with
Raven’s progressive matrices, and normal or corrected vision.
Exclusion criteria were additional neurological (cerebral
palsy, neurodegenerative diseases, or migraine), psychiatric
(intellectual disability, attention deficit/hyperactivity disorder,
specific learning disorder, anxiety, depression, and psychosis), or
other relevant medical conditions (endocrinopathies, metabolic,
hepatic, cardiac, or renal disorders) that could negatively affect
neuropsychological performances.
Two different epilepsy clinicians made the diagnosis using
clinical observations and electroencephalogram (EEG) reports
using the International League Against Epilepsy classification
(20). The subtyping of focal epilepsy was made by clinical history
and ictal and interictal scalp EEG characteristics.
The attending physician determined the quantity of PER for
each patient to prevent side effects and control seizures.
As habitual clinical practice, all the patients underwent a
standardized neuropsychological evaluation in order to assess
visuospatial skills [Rey–Osterrieth Complex Figure test (RCFT)]
before adding PER (baseline; n= 46) and after 12 months of drug
therapy (T1; n= 42).
At the same time, executive functions and non-verbal
intelligence were evaluated through EpiTrack Junior test and
standard progressive matrices (SPM).
The following factors were considered in our analysis: sex,
age, age at onset of seizures, duration of epilepsy, seizure
frequency, seizure types, seizure outcome, and concomitant PER
and ASMs dose.
All parents kept a diary of seizures and AEs. The efficacy
of PER treatment was measured considering the responder rate
(at least 50% reduction in seizure frequency); tolerability was
evaluated considering AEs reported by parents.
All participants were informed of the study objectives
and methods, and the parents signed informed consent.
The study complied with the rules of good clinical practice
of the Declaration of Helsinki and approved by the local
Ethics Committee.
RCFT
RCFT is a neuropsychological assessment in which visuospatial
perception and memory skills are assessed in both children and
adults (21, 22).
The subjects were given a pencil and a blank sheet of paper.
Subjects are initially asked to copy the figure (RCFT-Direct
Copy) and after 3min to reproduce it from memory (RCFT-
Immediate Recall). There is no time limit for this test. The
evaluation was based on 18 distinct elements of the figure, based
on a two-point scale for a maximum of 36 points. When the
graphic element is correct and positioned appropriately, two
points are awarded; when the element is incomplete, incorrectly
positioned, or distorted, one point is awarded; 0.5 points if
incomplete and in the wrong place; 0 points when the item is
missing or unrecognizable. Raw scores are converted to age-
based percentile scores.
EpiTrack Junior
EpiTrack Junior (23) is a test used to evaluate executive functions
suitable for monitoring drug treatment as it is very sensitive.
It consists of six tests (visual motor speed, inhibition, visual
motor planning, mental flexibility, working memory, and mental
fluency) from which an age-corrected total score is obtained.
The corrected total score is 49. An executive function deficit
is given by a total score below 32; in particular, a score from 31
to 29 indicates a mild deficit, and a score ≤28 points indicates
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a significant deficit. A significant change in two successive
measures is indicated by a loss of >2 points and a gain of
>3 points.
SPM
The Raven Progressive Matrices is a standardized tool used to
assess non-verbal intelligence in individuals ranging from age 5 to
adulthood (24). There are several versions; in our study, the SPM
composed of five series of 12 elements of increasing complexity
were used to analyze and encode visuospatial information.
Percentiles and age-weighted standard scores (mean = 100;
standard deviation = 15) were derived from the raw scores.
Scores ≥5th percentile or ≥70 standard are within the normal
range (25).
Statistical Analysis
All neuropsychological scores were reported as mean± standard
deviation (SD). The percentage of participants with a below
normal score (<2 SD) was considered. The Kolmogorov–
Smirnov test of normality was preliminarily performed to
establish the distribution of the data. Given the presence of some
data not normally distributed, non-parametric tests were used for
the analyses.
Yates’ corrected chi-square test was used for the comparison of
proportions. The mean score comparison was performed using
the Wilcoxon signed-rank test (paired samples) or the Mann–
Whitney U-test (independent sample). The comparison of the
mean scores in the independent samples was made with the
Kruskal–Wallis H-test.
The relationship between the different variables was evaluated
with the two-tailed Spearman rank correlation test. The
correlations were explained as follows: <0.2, low; 0.21–0.40, fair;
0.41–0.60, moderate; 0.61–0.80, good; 0.81–1.00, very good.
Statistical Package for Social Science software, version 23.0
(26) was used to analyze the data. Our hypotheses were tested
using Bonferroni adjusted alpha levels of 0.01 per test (0.05/5).
RESULTS
Sample Characteristics
We recruited 46 adolescents aged between 12 and 18 years (mean
age= 13.37± 1.51) affected by focal or generalized drug-resistant
epilepsy, who started PER as a first or second ASM for a better
seizure control. Two of them refused test administration at T1,
and two were lost to follow-up.
All demographic and clinical features of the participants
are summarized in Table 1; concomitant ASMs at baseline and
their modification after 12 months are reported in Table 2.
There were no significant differences between the main sample
characteristics at baseline and T1.
Seventy percent of patients had focal seizures (with or
without impaired awareness); the remaining 30% had generalized
seizures. PER was added as the first add-on in 17 patients (37%)
and as the second add-on in the remaining ones. Patients received
a variable dose of PER ranging from 2 to 8mg (mean dose= 3.40
± 1.17).
TABLE 1 | Demographic and clinical characteristics.




Male 24 (52%) 22 (52%) p = 0.846
Age (years) Wilcoxon
Mean (SD) 13.37 (1.51) 13.39 (1.51) p = 1.000
Age at onset of epilepsy
(years)
Wilcoxon




M (SD) 6.59 (4.25) 6.60 (4.34) p = 1.000
Seizure type χ2
Focal–aware 10 (22%) 8 (19%) p = 0.961
Focal–impaired awareness 22 (48%) 22 (52%) p = 0.830
Generalized 14 (30%) 12 (29%) p = 0.966
Lobe χ2
Temporal 23 (72%) 21 (70%) p = 0.906
Frontal 6 (19%) 6 (20%) p = 0.843
Occipital 3 (9%) 3 (10%) p = 0.728
Side χ2
Left 19 (59%) 17 (57%) p = 0.966




M (SD) Baseline 10.91 (6.38) 11.00 (6.91) p = 1.000
M (SD) T1 – 5.52 (5.90)
Seizure outcome
Seizure reduction >50% – 23 (55%)
Seizure free 6 (14%)
Antiseizure drug load
M (SD) Baseline
1.63 (0.49) 1.64 (0.48)









Lost at follow-up 4
Lost at follow-up 2
M, mean; SD, standard deviation; T0, baseline; T1, 12 months follow-up;
PER, perampanel.
After 12 months of PER therapy, 23 patients (55%) had
≥50% seizure reduction, and six were seizure-free (14%). No
significant AEs were reported with the exception of transient
irritability (n = 3) and dizziness (n = 2), which did not require
drug withdrawal.
Baseline Assessment
On balance, analyzing the results obtained in RCFT-Direct Copy,
a below normal score (<5th percentiles) was obtained by 13%
(6/46) of the patients, and 15% (7/46) showed a score at the
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TABLE 2 | Concomitant antiepileptic drug use at baseline and after 12 months
follow-up.
Concomitant ASM Baseline (N = 46) T1 (N = 42)
Levetiracetam (LEV) 18 (39%) 16 (38%)
Valproid acid (VPA) 16 (35%) 14 (33%)
Carbamazepine (CBZ) 11 (24%) 6 (14%)
Ethosuximide (ETS) 8 (17%) 4 (10%)
Oxcarbazepine (OXC) 7 (15%) 5 (12%)
Lamotrigine (LTG) 6 (13%) 4 (10%)
Topiramate (TPM) 5 (11%) 2 (5%)
Clobazam (CLB) 5 (11%) 4 (10%)
Lacosamide (LCM) 3 (6%) 3 (7%)
Perampanel (PER) 0 (0%) 42 (100%)
ASM, antiseizure medication; T1, 12 months follow-up.
TABLE 3 | Spearman correlation analysis.
Rey-Osterrieth complex figure test
(visual spatial skills)
Copy Recall
EpiTrack junior r = 0.614 r = 0.564
(Executive functions) p = 0.000* p = 0.000*
SPM r = 0.419 r = 0.211
(Non-verbal Intelligence) p = 0.004* p = 0.160
Age r = 0.215 r = 0.112
p = 0.151 p = 0.460
Age at onset r = 0.255 r = 0.192
p = 0.087 p = 0.200
Epilepsy Duration r = −0.236 r = −0.213
p = 0.114 p = 0.155
Seizure frequency r = −0.051 r = 0.142
p = 0.736 p = 0.347
ASM number r = −0.082 r = −0.129
p = 0.589 p = 0.392
Perampanel dose r = 0.039 r = 0.092
p = 0.797 p = 0.542
SPM, standard progressive matrices; ASM, antiseizure medication. Asterisks (*) mark
significant differences. Significant p value are in bold.
low limits of the norm (5th−15th percentiles). The RCFT-Direct
Copy mean score of the total sample at baseline was 29.09± 4.91.
The Spearman correlation test (Table 3) showed that RCFT-
Direct Copy score was significantly related to executive functions
(r = 0.614; p < 0.001) and non-verbal IQ (r = 0.419; p
< 0.001), and there was no significant association with age,
epilepsy duration, seizure frequency, age at onset of epilepsy, and
ASM number (Table 2; Figure 1). There was also no significant
difference in mean scores based on the following variables: sex
[Mann–Whitney U-test (n = 46), U = 232.5, p = 0.478], seizure
type [Mann–WhitneyU-test (n= 46),U = 153.5, p= 0.091], side
[Mann–Whitney U-test (n= 46), U = 96.5, p= 0.476], and lobe
of seizure onset [Kruskall–Wallis H-test (n = 46), H = 2.511, p
= 0.825].
Analyzing RCFT-Immediate Recall, we found that 24%
(11/46) of patients with epilepsy showed a score under the
norm (<5◦ percentiles), whereas 21% (8/46) showed a score
at the low limits of the norm (5–15◦percentiles). The RCFT-
Direct Copy mean score total at baseline was 15.52 ± 5.32.
The Spearman correlation test (Table 3) showed that the RCFT-
Immediate Recall scores were related to executive functions (r
= 0.564; p < 0.001), and there was no significant association
with non-verbal IQ, age, epilepsy duration, seizure frequency,
age at onset of epilepsy, and ASM number (Table 2; Figure 1).
There was also no significant difference in mean scores based
on the following variables: sex [Mann–Whitney U-test (n =
46), U = 219.5, p = 0.326], seizure type [Mann–Whitney
U-test (n = 46), U = 215.5, p = 0.839], side (Mann–
Whitney U-test (n = 46), U = 113.5, p = 0.984], and lobe
of seizure onset [Kruskall–Wallis H-test (n = 46), H = 0.243,
p= 0.886].
Comparison Between T1 and Baseline
After 12 months, a below normal RCFT-Direct Copy
score was obtained by 16% (7/42) of patients, and a
low-limit score of normal was obtained by 19% (8/42)
of patients; on the RCFT-Immediate Recall test, 20%
(9/42) of patients scored below normal (<5th percentiles),
and 24% (10/42) scored at the low limits of normal
(5th−15th percentiles).
After 12 months, we discovered that the RCFT-Direct Copy
and -Immediate Recall mean scores did not significantly differ
from baseline (Table 4; Figure 2). All the results are summarized
in Table 4.
DISCUSSION
With the insert of the new ASMs, which have similar
effectiveness in the seizure control, a good tolerability on the
cognitive profile is discriminating in the choice of the drug
therapy (14). This aspect is particularly important in pediatric
patients in which cognitive, executive, and visuospatial skills are
indispensable for good school achievement and a good quality of
life (27–29).
Our longitudinal observational study was based on 46
pediatric patients with focal or generalized drug-resistant
epilepsy evaluated with neuropsychological tests for visuospatial
perception and memory before and 12 months after the insert of
PER as the first or second addition.
Initially, a score below normal was obtained by 13 and 24%
of patients in visuospatial perception and memory, respectively,
and 15 and 21% of patients scored at the lower limits of normal
in these skills.
Our data confirm what has been already been described by
previous research, which demonstrated a global impairment of
visuospatial skills in epileptic patients compared with controls
(30, 31). In general, visuospatial abilities appear to be more
or less impaired even in children and adolescents with well-
controlled seizures (32). Our study, in keeping with the
study of Tallarita et al. (33), shows a greater impairment of
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FIGURE 1 | Correlation between Rey-Osterrieth complex figure test scores and Epitrack Junior or Standard progressive matrices scores.




N = 46 N = 42 T1 vs. Baseline
RCFT (visual spatial skills)
Copy Wilcoxon
M ± SD 29.09 ± 4.91 29.57 ± 3.76 Z = −0.897
0.370
Recall Wilcoxon
M ± SD 15.52 ± 5.32 15.76 ± 5.43 Z = −1.023
0.306
EPITRACK JUNIOR (executive functions)
M ± SD 28.98 ± 5.69
SPM (non-verbal Intelligence)
M ± SD 96.35 ± 9.38
RCFT, Rey-Osterrieth complex figure test; T1, 12 months follow-up; M, mean; SD,
standard deviation; SPM, standard progressive matrices.
visuospatial memory rather than visuospatial perception in
patients with epilepsy.
The correlation analysis in our sample showed that
visuospatial perception was significantly correlated with non-
verbal intelligence, and visuospatial memory was significantly
correlated with both non-verbal intelligence and executive
functions (e.g., attention, memory of work).
Impairment of executive functions in children and adolescents
with epilepsy has already been described in previous literature
studies (34). Our results suggest that visuospatial memory deficit
in adolescents with epilepsy could also be linked to impairment
of executive functions; however, future research should be
carried out to better investigate the extent and the nature of
this correlation.
In our sample, visuospatial perception and memory were not
significantly related to sex, age, epilepsy duration, age at onset
of epilepsy, seizure frequency, side and lobe of seizure onset,
and ASM number. The data from our study are in contrast
to other research, which suggests that greater impairment of
cognitive function may be caused by an earlier age of onset of
seizures, which affect a developing neuronal system (35, 36). The
relationship between impaired visuospatial memory capacity and
FIGURE 2 | Changes in visuospatial skills after perampanel addition.
the side/lobe of seizure onset is controversial (37). The study
by Völkl-Kernstock et al. (38) showed significant impairment in
visuospatial memory in children with benign childhood epilepsy
with centro-temporal spikes compared with controls, which did
not depend on the side of seizure onset and drug treatment.
Finally, unlike other literature studies, in our study there was
no relationship between the ASM number at baseline and
visuospatial functions.
However, all these aspects should be further investigated on
larger samples in order to increase statistical power.
In this study, at the 12-month reassessment, the visuospatial
perception and memory skills were not significantly mutated
from baseline, suggesting that PER does not have a negative
impact on these functions.
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Generally, the ASM number is negatively associated with
cognitive performance although some drugs have a better
tolerability profile than others (14).
The study of Meschede et al. (39) showed that also lacosamide
and PER did not determine an impairment in general cognitive
abilities. The subsequent study of Meador et al. (16) shows no
difference in the PER group vs. the placebo group in global
cognition skills, working memory, and attention.
Our previous experience also suggests that PER had a good
tolerability profile in adolescents with epilepsy, showing that,
after 12 months of add-on therapy with PER, there was no
worsening of executive functions and emotional–behavioral
profile (17).
Concerning specifically visuospatial skills, we recently
conducted an observational study on 207 pediatric patients
with different types of epilepsy well-controlled by antiseizure
monotherapy (40). In this study, we assessed visuospatial
memory and perception at time zero (before drug therapy)
and after 12 months of monotherapy with valproic acid,
levetiracetam, carbamazepine, ethosuximide, or oxcarbazepine.
At reassessment, subjects taking valproic acid, ethosuximide,
or carbamazepine performed significantly worse in visuospatial
memory, and subjects taking levetiracetam and oxcarbazepine
showed no significant changes.
In this perspective, our results are in line with our
previous study, according to which newer ASMs, such as PER,
levetiracetam, or oxcarbazepine have a better tolerability on
the cognitive profile compared to the older ASMs, such as
carbamazepine, valproic acid, and ethosuximide.
In the present study, PER was effective for seizure reduction
with a response rate of >50% in 23/42 subjects (55%), and 6/42
subjects are seizure-free (14%) after 12 months of therapy. No
significant side effects were reported.
Other studies controlled against placebo/other ASMs and with
larger sample sizes are needed to confirm our results.
CONCLUSIONS
In conclusion, PER was well-tolerated in adolescents with
focal and generalized seizures. Visuospatial memory and
perception were not significantly affected by PER therapy.
These results, therefore, suggest that PER has a good
tolerability contour in adolescence even in the medium/
long term.
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